SCHEMBL1008389

SCHEMBL1008389

NC(=O)c1sccc1NC(=O)CCCn1nc(C(F)(F)F)c2c1CCCC2

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
HTT P42858 1/20 0.55
POLB P06746 4/20 0.49
LMNA P02545 3/20 0.48
GAA P10253 2/20 0.48
TSHR P16473 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HSD17B10 Q99714 1/20 0.48
MAPT P10636 7/20 0.48
TP53 P04637 3/20 0.48
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
THRB P10828 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HTR1A P08908 1/20 0.45
HTR7 P34969 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1897850 0.97 ALDH1A1 (0.52) ALDH1A1HTTPOLBLMNAGAA
SCHEMBL1891359 0.89 POLB (0.62) POLBLMNAGAATSHRSMN1; SMN2
SCHEMBL1009775 0.83 LMNA (0.46) ALDH1A1HTTPOLBLMNAGAA
SCHEMBL1007126 0.81 ALDH1A1 (0.59) ALDH1A1HTTPOLBLMNAGAA
SCHEMBL12674148 0.80 MAPT (0.55) ALDH1A1HTTPOLBLMNAGAA
SCHEMBL1892539 0.80 MAPT (0.56) ALDH1A1HTTPOLBLMNAGAA
SCHEMBL1007635 0.80 POLB (0.61) ALDH1A1HTTPOLBLMNAGAA
SCHEMBL1059044 0.80 POLB (0.63) POLBLMNAGAATSHRSMN1; SMN2
SCHEMBL1006822 0.80 POLB (0.63) ALDH1A1HTTPOLBLMNAGAA
SCHEMBL1005578 0.79 GRM1 (0.66) ALDH1A1HTTLMNAGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
WO-2009119088-A1 HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 ALDH1A1 614/4885HTT 3487/4885POLB 3571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.